Compare FTAI Aviation Ltd (FTAI) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs McKesson Corporation — how do they compare? FTAI Aviation Ltd trades at $169.97 (market cap $17.57B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 6.2× FTAI Aviation Ltd's market cap, and FTAI Aviation Ltd pays the higher dividend (1.17%). Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 23 Days and McKesson Corporation for 74 Days on average.
| FTAI | MCK | |
|---|---|---|
Market Cap | $17.57B | $108.46B |
Volume | 1,905,014 | 712,607 |
Sector | Industrials | Health |
52-Week High | $310.04 | $995.69 |
52-Week Low | $152.80 | $725.17 |
Typical Hold Time | 23 Days | 74 Days |
Enterprise Value | $20.69B | $115.00B |
Dividend Yield | 1.17% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $171.06, down 2.16% amid a bearish technical signal, with support at $169 and resistance at $173. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS estimates. Recent developments include a $500M share buyback program and a 5-year Asia-Pacific maintenance deal with GMF, signaling strategic growth initiatives.
The outlook is mixed: robust analyst consensus (100% buy ratings, $321.25 price target) and shareholder-friendly actions support upside, but consecutive earnings misses, negative operating cash flow, and high valuation ratios (P/E 37.35) pose risks. Investors should weigh growth in aerospace segments against execution challenges and macroeconomic headwinds.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
